Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) EBT Margin (2020 - 2024)

Goldenwell Biotech (GWLL) has disclosed EBT Margin for 5 consecutive years, with 44344.94% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBT Margin fell 3634532.0% year-over-year to 44344.94%, compared with a TTM value of 14229.75% through Sep 2025, up 893722.0%, and an annual FY2024 reading of 94602.88%, down 8821067.0% over the prior year.
  • EBT Margin was 44344.94% for Q4 2024 at Goldenwell Biotech, down from 17515.15% in the prior quarter.
  • Across five years, EBT Margin topped out at 22392.55% in Q4 2022 and bottomed at 44344.94% in Q4 2024.
  • Average EBT Margin over 5 years is 6026.79%, with a median of 2641.65% recorded in 2023.
  • The sharpest move saw EBT Margin surged 2348918bps in 2022, then crashed -3634532bps in 2024.
  • Year by year, EBT Margin stood at 2920.0% in 2020, then soared by 62bps to 1096.62% in 2021, then soared by 2142bps to 22392.55% in 2022, then tumbled by -136bps to 7999.62% in 2023, then plummeted by -454bps to 44344.94% in 2024.
  • Business Quant data shows EBT Margin for GWLL at 44344.94% in Q4 2024, 17515.15% in Q2 2024, and 7999.62% in Q4 2023.